Literature DB >> 2225561

Membranous glomerulonephritis induced by 2-mercaptopropionylglycine (2-MPG).

A Lindell1, T Denneberg, S Eneström, C Fich, T Skogh.   

Abstract

Thirty-two patients suffering from cystinuria were treated with 2-mercaptopropionylglycine (2-MPG) for 0.5-10 years (average 6.3 years). After 4-14 months of treatment at daily doses ranging from 500 to 2500 mg, three patients developed slight to moderate proteinuria. Two patients were subjected to renal biopsy which showed membranous glomerulonephritis. In one biopsy signs of progressive glomerular lesions were observed. In seven patients (22%) antinuclear antibodies were demonstrated. In one patient with biopsy-proven membranous glomerulonephritis, the antinuclear antibodies consisted of antihistone antibodies. The observations presented in this report indicate that 2-MPG, like D-penicillamine, could induce autoimmune reactions, in some cases leading to membranous glomerulonephritis. The prognosis seemed to be favorable. However, the occurrence of irreversible glomerular lesions as reported by us should be borne in mind when considering long-term treatment with 2-MPG. A continuous, close follow-up of patients on 2-MPG treatment is recommended.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225561

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  4 in total

1.  Measurement of diurnal variations in urinary cystine saturation.

Authors:  A Lindell; T Denneberg; J O Jeppsson; H G Tiselius
Journal:  Urol Res       Date:  1995

2.  Cystone® for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers.

Authors:  Stephen B Erickson; Terri J Vrtiska; Vincent J Canzanello; John C Lieske
Journal:  Urol Res       Date:  2010-12-16

3.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Clinical course and cystine stone formation during tiopronin treatment.

Authors:  A Lindell; T Denneberg; E Hellgren; J O Jeppsson; H G Tiselius
Journal:  Urol Res       Date:  1995
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.